Altre lingue Curasight A/S

Azioni

CURAS

DK0061295797

Prezzo di chiusura NORDIC GROWTH MARKET Altri mercati azionari 00:00:00 03/05/2024			Variaz. 5gg	Var. 1 gen.
9,96 ^DKK	+0,20%		+9,45%	-43,89%

16/04	Curasight A/S annuncia l'approvazione della domanda di sperimentazione clinica (CTA) per la sperimentazione di fase 2 con uTRACE nei pazienti con cancro alla prostata	CI
12/04	Curasight A/S annuncia cambiamenti nel Consiglio di Amministrazione	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial	22/04
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	16/04
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	16/04
Curasight announces change in the Board of Directors	12/04
Curasight A/S Announces Board Changes	12/04
BioStock: Curasight cancels rights issue and evaluates alternative financing	13/03
Curasight not to proceed with rights issue; evaluating alternative financing opportunities	11/03
Notice of Annual General Meeting 2024	06/03
The subscription period in Curasight's rights issue begins today	23/02
Curasight publishes information memorandum in connection with forthcoming rights issue	22/02
Annual Report for the fiscal year 2023	22/02
Year-end report October - December 2023	22/02
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise	19/02
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	13/02
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	13/02
Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company	13/02
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	13/02
BioStock: Curasight gets first milestone payment from Curium	02/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Curasight A/S

Azioni

CURAS

DK0061295797

Altre lingue

Filtri